- Sight Sciences Inc SGHT announced 36-month post-surgery follow-up results of the OMNI Surgical System.
- The data demonstrates that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis.
- The study showed that canaloplasty followed by trabeculectomy using the OMNI Surgical System achieved a mean reduction in intraocular pressure (IOP) of at least 20% for all 26 patients (38 eyes) at 36 months follow-up.
- The post-operative IOP and medication use reduction at 12 months remained consistent over three years, suggesting robust, durable effectiveness of the OMNI Surgical System.
- A minimal number of adverse events were reported, all resolved without intervention except one eye required secondary IOP lowering intervention.
- Price Action: SGHT shares are down 2.86% at $8.51 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in